var data={"title":"Entecavir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Entecavir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6107?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=entecavir-drug-information\" class=\"drug drug_general\">see &quot;Entecavir: Drug information&quot;</a> and <a href=\"topic.htm?path=entecavir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Entecavir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708732\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Severe acute exacerbations of hepatitis B:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti&ndash;hepatitis B therapy, including entecavir. Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients who discontinue anti&ndash;hepatitis B therapy. If appropriate, initiation of antihepatitis B therapy may be warranted.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">HIV and chronic hepatitis B virus coinfection:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Limited clinical experience suggests there is a potential for the development of resistance to HIV nucleoside reverse transcriptase inhibitors if entecavir is used to treat chronic hepatitis B virus (HBV) infection in patients with HIV infection not being treated. Therapy with entecavir is not recommended for HIV/HBV coinfected patients who are not also receiving antiretroviral therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis and hepatomegaly:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors alone or in combination with antiretrovirals.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165232\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Baraclude</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4297830\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Entecavir;</li>\n      <li>Auro-Entecavir;</li>\n      <li>Baraclude;</li>\n      <li>PMS-Entecavir</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010948\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010976\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=entecavir-drug-information\" class=\"drug drug_general\">see &quot;Entecavir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Oral tablets and solution may be used interchangeably on a mg:mg basis.</p>\n    <p style=\"text-indent:0em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis B infection (HBV), chronic:</b> Oral: <b>Note:</b> Optimal duration of treatment not established for nucleoside analogs, a minimum of 12 months and typically longer required; consolidation therapy of at least 6 months after seroconversion and complete viral suppression has been suggested (Jonas 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 2 to &lt;16 years with compensated liver diseases:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment naive:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">10 to 11 kg: 0.15 mg  oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;11 to 14 kg: 0.2 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;14 to 17 kg: 0.25 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;17 to 20 kg: 0.3 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;20 to 23 kg: 0.35 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;23 to 26 kg: 0.4 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;26 to 30 kg: 0.45 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 kg: 0.5 mg oral solution or tablet once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lamivudine-experienced:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">10 to 11 kg: 0.3 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;11 to 14 kg: 0.4 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;14 to 17 kg: 0.5 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;17 to 20 kg: 0.6 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;20 to 23 kg: 0.7 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;23 to 26 kg: 0.8 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;26 to 30 kg: 0.9 mg oral solution once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;30 kg: 1 mg oral solution or tablet once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nucleoside treatment na&iuml;ve with compensated liver disease: 0.5 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lamivudine-refractory or known lamivudine or telbivudine-resistant mutations: 1 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV/Hepatitis B virus coinfection:</b> Limited data available: <b>Note: </b>Only recommended in patients who cannot take tenofovir; must be used in addition to a fully suppressive antiretroviral therapy regimen (DHHS [adult/pediatric] 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nucleoside treatment naive: Adolescents: 0.5 mg once daily (DHHS [adult] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lamivudine-refractory or -resistant with decompensated liver disease: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 12 years of age: 0.5 mg once daily (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 1 mg once daily (DHHS [adult] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HBV reinfection prophylaxis, postliver transplant (with or without HBIG):</b> Limited data available: Adolescents &ge;16 years: Oral: 1 mg once daily has been reported in an open-label trial of 65 patients (age range: 16 years and older); however, a lower dose of 0.5 mg once daily has also been used in adult patients (age range: 23 to 65 years) (Fung 2011; Perrillo 2012).</p>\n    <p style=\"text-indent:0em;\">Adult: <b> Hepatitis B virus (HBV) infection, treatment:</b> Oral:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Nucleoside treatment naive: 0.5 mg once daily</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Lamivudine-refractory or -resistant viremia (or known lamivudine- or telbivudine-resistant mutations): 1 mg once daily</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Decompensated liver disease: 1 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Treatment duration (AASLD Practice Guidelines [Lok], 2009):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HBsAg) clearance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Decompensated liver disease: Lifelong treatment is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Patients not achieving a primary response (&lt;2 log decrease in serum HBV DNA) after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal  impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling;  insufficient data to recommend a specific dose adjustment in pediatric patients with renal impairment; a reduction in the dose or an increase in the dosing interval similar to adjustments for adults should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Daily dosage regimen preferred:    </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;50 mL/minute:  No adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 49 mL/minute: Administer 50% of usual dose once daily or administer the normal dose every 48 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 29 mL/minute: Administer 30% of usual dose once daily or administer the normal dose every 72 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Administer 10% of usual dose once daily or administer the normal dose every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis and peritoneal dialysis (CAPD):  Minimally removed by hemodialysis (13% over 4 hours) and CAPD (0.3% over 7 days): Administer 10% of usual dose once daily or administer the normal dose every 7 days; administer after hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children &ge; 2 years, Adolescents, and Adults: No adjustment necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165216\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Baraclude: 0.05 mg/mL (210 mL) [contains methylparaben, propylparaben; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Baraclude: 0.5 mg, 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165206\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010982\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer on an empty stomach (2 hours before or after a meal). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Do not dilute or mix oral solution with water or other beverages; use calibrated oral dosing syringe.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132423\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165228\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. After opening, oral solution can be used up to expiration date on the bottle.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010949\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of chronic hepatitis B infection with evidence of active viral replication and either evidence of persistent transaminase elevations or histologically active disease (FDA approved in ages &ge;2 years weighing &ge;10 kg and adults). <b>Note:</b> In children, indication is based on data in patients with compensated liver disease only; in adults, indication is based on data in patients with compensated and decompensated liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165249\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse reactions are generally similar in adult and pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Peripheral edema (with decompensated liver disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Decreased serum bicarbonate (with decompensated liver disease), glycosuria, hyperglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, increased serum amylase, increased serum lipase, nausea, unpleasant taste, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Ascites (with decompensated liver disease), increased serum ALT, increased serum bilirubin, hepatic encephalopathy </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Hepatic carcinoma (with decompensated liver disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Upper respiratory tract infection (with decompensated liver disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever (with decompensated liver disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Alopecia, anaphylactoid reaction, hepatomegaly, insomnia, lactic acidosis, macular edema (Muqit, 2011), renal failure, thrombocytopenia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165220\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canadian labeling: Hypersensitivity to entecavir or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165208\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: <b>[US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with nucleoside analogue inhibitors;</b> use with caution in patients with risk factors for liver disease (risk may be increased with female gender, decompensated liver disease, obesity, or prolonged nucleoside inhibitor exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis B: <b>[US Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation of antihepatitis B therapy, including entecavir. Monitor liver function for at least several months after stopping treatment; reinitiation of antihepatitis B therapy may be required.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV: <b>[US Boxed Warning]: May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection.</b> Determine HIV status prior to initiating treatment with entecavir. <b>Not recommended for HIV/HBV coinfected patients unless also receiving antiretroviral therapy. </b>The manufacturer's labeling states that entecavir does not exhibit any clinically-relevant activity against human immunodeficiency virus (HIV type 1). However, a small number of case reports have indicated declines in virus levels during entecavir therapy. HIV resistance to a common HIV drug has been reported in an HIV/HBV-infected patient receiving entecavir as monotherapy for HBV.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Dose adjustment not required. Limited data supporting treatment of chronic hepatitis B in patients with decompensated liver disease; observe for increased adverse reactions, including hepatorenal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment or patients receiving concomitant therapy which may reduce renal function; dose adjustment recommended for CrCl &lt;50 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Children: There are limited data available on the use of entecavir in lamivudine-experienced pediatric patients; use in these patients only if the potential benefit justifies the potential risk to the child.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resistance: Cross-resistance may develop in patients failing previous therapy with lamivudine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299265\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3053493\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=93384&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165229\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food delays absorption and reduces AUC by 18% to 20%. Management: Administer on an empty stomach 2 hours before or after a meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165213\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165221\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects have been observed in animal studies. Information related to use in pregnancy is limited; use only if other options are inappropriate (DHHS [OI], 2013). Pregnant women taking entecavir should enroll in the pregnancy registry by calling 1-800-258-4263.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010984\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">HIV status (prior to initiation of therapy); liver function tests, renal function; in HBV/HIV-coinfected patients, monitor HIV viral load and CD4 count; HBeAg, HBV DNA; in patients with lamivudine-refractory or -resistant viremia (or known lamivudine- or telbivudine-resistance mutations) entecavir resistance can develop rapidly. Monitor HBV DNA every 3 months (DHHS [adults], 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165207\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Entecavir is intracellularly phosphorylated to guanosine triphosphate which competes with natural substrates to effectively inhibit hepatitis B viral polymerase; enzyme inhibition blocks reverse transcriptase activity thereby reducing viral DNA synthesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165219\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Note:</b> The pharmacokinetics of pediatric patients &ge;2 years are similar to adult values. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Delayed with food; C<sub>max</sub> decreased 44% to 46%, AUC decreased 18% to 20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Extensive (V<sub>d</sub> in excess of body water) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~13% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minor hepatic glucuronide/sulfate conjugation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Tablet and oral solution are bioequivalent. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: ~5-6 days; accumulation: ~24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 0.5-1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (60% to 73% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422226\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Baraclude Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/mL (210 mL): $1,152.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Baraclude Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (30): $1,646.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $1,646.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Entecavir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (30): $1,333.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $1,333.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4301433\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agicarvir (VN);</li>\n      <li>Bacavir (KR);</li>\n      <li>Baraclude (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VN);</li>\n      <li>Baracross (PH);</li>\n      <li>Baraenter (KR);</li>\n      <li>Baraliver (KR);</li>\n      <li>Baratis Film (KR);</li>\n      <li>Barcavir (BD);</li>\n      <li>Encavir (KR);</li>\n      <li>Encavor (HK);</li>\n      <li>Enped (KR);</li>\n      <li>Entavir (BD);</li>\n      <li>Enteca (KR);</li>\n      <li>Entecabell (KR);</li>\n      <li>Enteclud (VN);</li>\n      <li>Entegard (PH);</li>\n      <li>Enteone (KR);</li>\n      <li>Entikav (HK);</li>\n      <li>Nulesavir (VN);</li>\n      <li>Tecavir (BD);</li>\n      <li>Teviral (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baraclude (entecavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chu M, Cho SM, Choe B, et al. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.  <i>J Pediatr Gastroenterol Nutr</i>. 2012;55:648-652.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/22688509/pubmed\" target=\"_blank\" id=\"22688509\">22688509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA),&quot; May 7, 2013. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. <i>Gastroenterology</i>. 2011;141(4):1212-1219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/21762659/pubmed\" target=\"_blank\" id=\"21762659\">21762659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. <i>Hepatology</i>. 2010;52(6):2192-2205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/20890947/pubmed\" target=\"_blank\" id=\"20890947\">20890947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. <i>Hepatology</i>. 2009;50(3):661-662.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/19714720/pubmed\" target=\"_blank\" id=\"19714720\">19714720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muqit  MK, Stanga PE, Vilar FJ, et al. Presumed entecavir-induced ocular toxicity. <i>Eye (Lond)</i>. 2011;25(12):1665-1668.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/22020173/pubmed\" target=\"_blank\" id=\"22020173\">22020173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pawlowska M, Halota W, Smukalska E, et al. HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. <i>Eur J Clin Microbiol Infect Dis</i>. 2012;31:571-574.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/21796345/pubmed\" target=\"_blank\" id=\"21796345\">21796345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrillo R, Buti M, Durand F, et al. Entecavir and hepatits B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. <i>Liver Transplant</i>.  2013;19:887-895.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/23788462/pubmed\" target=\"_blank\" id=\"23788462\">23788462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 93384 Version 90.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708732\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F165232\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4297830\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1010948\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1010976\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F165216\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F165206\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1010982\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132423\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F165228\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1010949\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F165249\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F165220\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F165208\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299265\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3053493\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F165229\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F165213\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F165221\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1010984\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F165207\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F165219\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422226\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4301433\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/93384|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=entecavir-drug-information\" class=\"drug drug_general\">Entecavir: Drug information</a></li><li><a href=\"topic.htm?path=entecavir-patient-drug-information\" class=\"drug drug_patient\">Entecavir: Patient drug information</a></li></ul></div></div>","javascript":null}